Previous 10 | Next 10 |
home / stock / kros / kros articles
Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceu...
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company...
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company ...
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical...
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial res...
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) r...
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company...
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene thera...
News, Short Squeeze, Breakout and More Instantly...
Keros Therapeutics Inc. Company Name:
KROS Stock Symbol:
NASDAQ Market:
Keros Therapeutics Inc. Website:
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...